Welcome to CDC stacks | Evolution of Cryptococcal Antigen Testing: What is new? - 39436 | CDC Public Access

Welcome to CDC stacks | Evolution of Cryptococcal Antigen Testing: What is new? - 39436 | CDC Public Access

Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov

Advanced Search

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

information icon

information icon

information icon

Clear All Simple Search

Advanced Search

delete_icon

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Evolution of Cryptococcal Antigen Testing: What is new?

Published Date:

Apr 12 2016

Source:

Curr Fungal Infect Rep. 10(2):62-67.

[PDF-308.89 KB]

Details:

Personal Authors:

Nalintya, Elizabeth ; Kiggundu, Reuben ; Meya, David ;

Keywords:

[+]

Pubmed ID:

27158322

Pubmed Central ID:

PMC4858186

Description:

Over the last decade, an upsurge in both the frequency and severity of fungal infections due to the HIV/AIDS epidemic and the use of immunosuppressive therapy has occurred. Even diagnostic methods like culture and microscopy, which have low sensitivity and longer turn-around-times are not widely available, leading to delays in timely antifungal therapy and detrimental patient outcomes. The evolution of cryptococcal antigen (CrAg) testing to develop inexpensive and more sensitive methods to detect cryptococcal antigen is significant. These newer tests employ immunoassays as part of point-of-care platforms, which do not require complex laboratory infrastructure and they have the potential to detect early disease and reduce time to diagnosis of cryptococcal infection. Advocacy for widely available and efficacious life-saving antifungal treatment should be the only remaining challenge.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

U01 GH000517/GH/CGH CDC HHS/United States

Supporting Files:

nihms-777332.nxml

text/xml

No Related Documents.

You May Also Like:

Preventing Cryptococcosis—Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy

Personal Author:

Meya, David; Rajasingham, Radha; Nalintya, Elizabeth; Tenforde, Mark; Jarvis, Joseph N;

Published:

2015

Source:

Curr Trop Med Rep. 2(2):81-89.

Description:

Cryptococcosis remains a significant cause of morbidity and mortality among HIV-infected patients, especially in sub-Saharan Africa where it causes up to 20 % of AIDS-related deaths in HIV programs. A new, highly sensitive, and affordable point of c...

File Type:

[PDF - 261.55 KB]
CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis

Personal Author:

Ford, Nathan; Shubber, Zara; Jarvis, Joseph N; Chiller, Tom; Greene, Greg; Migone, Chantal; Vitoria, Marco; Doherty, Meg; Meintjes, Graeme;

Published:

Mar 04 2018

Source:

Clin Infect Dis. 2018; 66(Suppl 2):S152-S159.

Description:

Background : Current guidelines recommend screening all people living with human immunodeficiency virus (PLHIV) who have a CD4 count ≤100 cells/µL for cryptococcal antigen (CrAg) to identify those patients who could benefit from preemptive flucona...

File Type:

[PDF - 2.31 MB]
Cryptococcal screening program training manual

Corporate Author:

National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Foodborne, Waterborne, and Environmental Diseases.

Published:

08/2012

Description:

Cryptococcus is a fungus, found in the soil, which produces spores that can be inhaled. If a person’s immune system is weakened (for example, by HIV), Cryptococcus can cause a life-threatening infection in the brain called cryptococcal meningitis. ...

File Type:

[PDF - 9.81 MB]
Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: A feasibility study in rural Lesotho

Personal Author:

Rick, Fernanda; Niyibizi, Aline Aurore; Shroufi, Amir; Onami, Kazumi; Steele, Sarah-Jane; Kuleile, Malehlohonolo; Muleya, Innocent; Chiller, Tom; Walker, Tiffany; Van Cutsem, Gilles;

Published:

Sep 06 2017

Source:

PLoS One. 12(9).

Description:

Introduction : Cryptococcal meningitis is one of the leading causes of death among people with HIV in Africa, primarily due to delayed presentation, poor availability and high cost of treatment. Routine cryptococcal antigen (CrAg) screening of patien...

File Type:

[PDF - 1.31 MB]
Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial

Personal Author:

Mermin, Jonathan; Ekwaru, John P; Were, Willy; Degerman, Richard; Bunnell, Rebecca; Kaharuza, Frank; Downing, Robert; Coutinho, Alex; Solberg, Peter; Alexander, Lorraine N; Tappero, Jordan; Campbell, James; Moore, David M;

Published:

Nov 09 2011

Source:

BMJ. 2011; 343.

Description:

To evaluate the use of routine laboratory monitoring in terms of clinical outcomes among patients receiving antiretroviral therapy (ART) in Uganda.|Randomised clinical trial|A home based ART programme in rural Uganda.|All participants were people wit...

File Type:

[PDF - 492.56 KB]